Drug Profile
Research programme: obesity therapy - LG Chem
Alternative Names: LB-53280Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator LG Life Sciences
- Developer LG Chem; Takeda
- Class
- Mechanism of Action Melanocortin type 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for preclinical development in Obesity in China
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in South Korea (PO)
- 28 Aug 2015 Preclinical trials in Obesity in China (PO)